These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 6972418)

  • 1. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome.
    Schlievert PM; Shands KN; Dan BB; Schmid GP; Nishimura RD
    J Infect Dis; 1981 Apr; 143(4):509-16. PubMed ID: 6972418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Staphylococcal pyrogenic exotoxin type C: further characterization.
    Schlievert PM; Kelly JA
    Ann Intern Med; 1982 Jun; 96(6 Pt 2):982-6. PubMed ID: 7091979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification and characterization of staphylococcal pyrogenic exotoxin type B.
    Schlievert PM
    Biochemistry; 1980 Dec; 19(26):6204-8. PubMed ID: 6781533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification and characterization of Staphylococcus aureus FRI 1169 and 587 toxic shock syndrome exotoxins.
    Igarashi H; Fujikawa H; Usami H; Kawabata S; Morita T
    Infect Immun; 1984 Apr; 44(1):175-81. PubMed ID: 6200439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolution of highly purified toxic-shock syndrome toxin 1 into two distinct proteins by isoelectric focusing.
    Blomster-Hautamaa DA; Kreiswirth BN; Novick RP; Schlievert PM
    Biochemistry; 1986 Jan; 25(1):54-9. PubMed ID: 3954993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of staphylococcal enterotoxin F and pyrogenic exotoxin C by Staphylococcus aureus isolates from toxic shock syndrome-associated sources.
    Bonventre PF; Weckbach L; Staneck J; Schlievert PM; Thompson M
    Infect Immun; 1983 Jun; 40(3):1023-9. PubMed ID: 6189784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification and physicochemical and biological characterization of a staphylococcal pyrogenic exotoxin.
    Schlievert PM; Schoettle DJ; Watson DW
    Infect Immun; 1979 Mar; 23(3):609-17. PubMed ID: 457253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and biological properties of a new staphylococcal exotoxin.
    Ren K; Bannan JD; Pancholi V; Cheung AL; Robbins JC; Fischetti VA; Zabriskie JB
    J Exp Med; 1994 Nov; 180(5):1675-83. PubMed ID: 7964453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proinflammatory exoprotein characterization of toxic shock syndrome Staphylococcus aureus.
    Lin YC; Anderson MJ; Kohler PL; Strandberg KL; Olson ME; Horswill AR; Schlievert PM; Peterson ML
    Biochemistry; 2011 Aug; 50(33):7157-67. PubMed ID: 21749039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Group B streptococcal toxic shock-like syndrome: report of a case and purification of an associated pyrogenic toxin.
    Schlievert PM; Gocke JE; Deringer JR
    Clin Infect Dis; 1993 Jul; 17(1):26-31. PubMed ID: 8353243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Staphylococcal toxic shock exotoxin (its isolation and characteristics)].
    Akatov AK; Fluer FS; Ratgauz GL; Kushko IV
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Oct; (10):15-20. PubMed ID: 3541462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitosan malate inhibits growth and exotoxin production of toxic shock syndrome-inducing Staphylococcus aureus strains and group A streptococci.
    Schlievert PM
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3056-62. PubMed ID: 17576832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaginal isolates of Staphylococcus aureus associated with toxic shock syndrome.
    Barbour AG
    Infect Immun; 1981 Aug; 33(2):442-9. PubMed ID: 6456228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification and characterization of group A streptococcal pyrogenic exotoxin type C.
    Schlievert PM; Bettin KM; Watson DW
    Infect Immun; 1977 May; 16(2):673-9. PubMed ID: 324918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of toxic shock toxin in toxic shock and other clinical strains of Staphylococcus aureus.
    Reeves MW; Pine L; Feeley JC; Wells DE
    Infect Immun; 1984 Nov; 46(2):590-7. PubMed ID: 6500702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification and some physicochemical properties of toxic-shock toxin.
    Reiser RF; Robbins RN; Khoe GP; Bergdoll MS
    Biochemistry; 1983 Aug; 22(16):3907-12. PubMed ID: 6615808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preparation and properties of the staphylococcal toxin causing the toxic shock syndrome].
    Fan'kovskaia MK; Ezepchuk IuV; Solov'eva MN; Shcheglovitova ON
    Mol Gen Mikrobiol Virusol; 1987 Jul; (7):23-7. PubMed ID: 3670320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Staphylococcus aureus isolates from patients with toxic shock syndrome, using polyethylene infection chambers in rabbits.
    Scott DF; Kling JM; Kirkland JJ; Best GK
    Infect Immun; 1983 Jan; 39(1):383-7. PubMed ID: 6822419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of human interleukin-1 by toxic-shock-syndrome toxin-1.
    Parsonnet J; Hickman RK; Eardley DD; Pier GB
    J Infect Dis; 1985 Mar; 151(3):514-22. PubMed ID: 3871826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses.
    Bohach GA; Fast DJ; Nelson RD; Schlievert PM
    Crit Rev Microbiol; 1990; 17(4):251-72. PubMed ID: 2206394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.